Business Wire

betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All ...

betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented ...
Nasdaq

FDA Panel Endorses Bluebird Bio's Beti-cel Gene Therapy For Rare Blood Disease

(RTTNews) - An advisory committee to the U.S. Food and Drug Administration voted unanimously to recommend approval of bluebird bio Inc.'s (BLUE) beti-cel gene therapy for people with beta-thalassemia ...
Business Wire

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of ...

All four parent studies are complete, and all patients have transitioned to a long-term follow-up study (LTF-303) SOMERVILLE, Mass.--(BUSINESS WIRE)--Updated data from bluebird bio inc.’s (NASDAQ: ...
FiercePharma

FDA extends decision dates on bluebird bio's gene therapy drugs beti-cel and eli-cel by 3 months

Bluebird Bio will have to wait an extra three months to gain potential approvals for its breakthrough gene therapies beti-cel and eli-cel. The FDA has extended its review period for the lentiviral ...